Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)

Travera Inc200 enrolled

Overview

The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using isolated tumor cells from various specimen formats including malignant fluids such as pleural effusions and ascites, core needle biopsies, fine needle aspirates, or resections.

Study Type

OBSERVATIONAL

Enrollment

200

Conditions

Pleural Effusion, Malignant Ascites, Malignant Carcinoma Carcinoma, Hepatocellular Carcinoma, Renal Cell Carcinoma, Renal Carcinoma, Small Cell Carcinoma, Non-Small-Cell Lung

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Patient is ≥18 years of age 2. Written Informed Consent provided by patient 3. Diagnosis of any kind of carcinoma 4. Malignant fluid (e.g. pleural effusion or ascites) drainage OR tumor tissue resection OR tumor tissue needle biopsy is clinically indicated as part of SOC 5. Proceeding onto therapy for treatment 6. Informed consent obtained for the XCELSIOR longitudinal outcomes registry (NCT03793088) Exclusion Criteria: 1. Lack of informed consent 2. Unable to obtain sufficient sample

Outcomes

Primary Outcomes

BOR

Best overall response

Time frame: 12 months

Secondary Outcomes

PFS

Progression Free Survival

Time frame: 24 months

Central Contacts

Mark Stevens, Phd

CONTACT

6172999784 mstevens@travera.com

Rob Kimmerling, Phd

CONTACT

rkimmerling@travera.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.